Acasti Pharma Inc. Class A - ADR Key Ratios
$3.28
As on 21-Nov-2024 09:30EDT
Market cap
$34 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.6
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -- | -- | -- |
| EBIT | -- | -- | -152.17 | 8.04 | 10.33 |
| Net Profit | -31.14 | 7.72 | 71.50 | -1.86 | 11.87 |
| EPS | -- | -- | -- | -- | -- |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Mar-24 | Mar-23 |
| EBIT-Margin
| -162,647.65 | -84,699.02 | -- | -- | -- |
| Net Margin
| -- | -- | -- | -- | -- |
| Return on equity
| -26.65 | -71.39 | -19.69 | -19.82 | -48.15 |
| Return on Capital
| -26.55 | -68.64 | -- | -19.75 | -47.94 |
| Return on Assets
| -22.66 | -40.24 | -15.72 | -16.86 | -40.85 |
| Debt to Equity (x)
| -- | -- | 0.00 | -- | 0.01 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Acasti Pharma Inc. Class A - ADR
|
--
|
-19.75
|
-47.94
|
-11.95
|
-57.13
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-19.69
Lower than Peers by 14.30
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Acasti Pharma Inc. Class A - ADR
|
-19.69
|
-19.82
|
-48.15
|
-11.98
|
-57.33
|
|
Peer Median
|
-5.39
|
--
|
--
|
--
|
--
|
ROA
-15.72
Lower than Peers by 10.67
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Acasti Pharma Inc. Class A - ADR
|
-15.72
|
-16.86
|
-40.85
|
-10.28
|
-46.13
|
|
Peer Median
|
-5.06
|
--
|
--
|
--
|
--
|
EBIT Margin
--
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Acasti Pharma Inc. Class A - ADR
|
--
|
--
|
--
|
-162,647.65
|
-6,750.40
|
|
Peer Median
|
-7.31
|
--
|
--
|
--
|
--
|
Net Margin
--
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Acasti Pharma Inc. Class A - ADR
|
--
|
--
|
--
|
-75,530.77
|
-10,039.80
|
|
Peer Median
|
-0.44
|
--
|
--
|
--
|
--
|
Revenue Growth
--
--
Year on year growth in net sales
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Acasti Pharma Inc. Class A - ADR
|
--
|
--
|
-1.00
|
-0.93
|
--
|
|
Peer Median
|
18.01
|
--
|
--
|
--
|
--
|
EBIT Growth
-152.17
Lower than Peers by 162.45
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Acasti Pharma Inc. Class A - ADR
|
-152.17
|
-171.95
|
174.36
|
-59.81
|
45.86
|
|
Peer Median
|
10.28
|
--
|
--
|
--
|
--
|
Net Profit Growth
71.50
Higher than Peers by 19.41
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Acasti Pharma Inc. Class A - ADR
|
71.50
|
69.71
|
-332.11
|
50.10
|
23.61
|
|
Peer Median
|
52.09
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Acasti Pharma Inc. Class A - ADR
|
--
|
--
|
0.01
|
0.00
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Acasti Pharma Inc. Class A - ADR
|
--
|
--
|
0.00
|
0.00
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
6.01
Higher than Peers by 0.72
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Acasti Pharma Inc. Class A - ADR
|
6.01
|
14.26
|
8.59
|
13.97
|
39.50
|
|
Peer Median
|
5.29
|
--
|
--
|
--
|
--
|
Quick Ratio
6.01
Higher than Peers by 0.68
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Acasti Pharma Inc. Class A - ADR
|
6.01
|
--
|
--
|
--
|
--
|
|
Peer Median
|
5.32
|
--
|
--
|
--
|
--
|
Interest Coverage
-16.85
Lower than Peers by 18.04
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Acasti Pharma Inc. Class A - ADR
|
-16.85
|
-12.42
|
0.23
|
-94.39
|
-50.12
|
|
Peer Median
|
1.19
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
--
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Acasti Pharma Inc. Class A - ADR
|
--
|
--
|
--
|
4,215.38
|
270.41
|
|
Peer Median
|
22.86
|
--
|
--
|
--
|
--
|
Asset Turnover
--
--
Sales / Average Total Assets
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Acasti Pharma Inc. Class A - ADR
|
--
|
--
|
--
|
0.00
|
0.00
|
|
Peer Median
|
0.11
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Acasti Pharma Inc. Class A - ADR
|
--
|
--
|
--
|
15,143.83
|
1,002.57
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Acasti Pharma Inc. Class A - ADR
|
--
|
--
|
--
|
--
|
5,276.90
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Acasti Pharma Inc. Class A - ADR
|
--
|
37,338.51
|
10.22
|
21.00
|
4,392.61
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Acasti Pharma Inc. Class A - ADR
|
--
|
--
|
--
|
--
|
1,886.86
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Book Value
0.59
Lower than Peers by 3.05
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Acasti Pharma Inc. Class A - ADR
|
0.59
|
--
|
--
|
--
|
--
|
|
Peer Median
|
3.64
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Acasti Pharma Inc. Class A - ADR
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-0.56
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Acasti Pharma Inc. Class A - ADR
|
-0.56
|
2.04
|
-1.73
|
2.17
|
4.93
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
34
Lower than Peers by 69
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Acasti Pharma Inc. Class A - ADR
|
34
|
--
|
--
|
--
|
--
|
|
Peer Median
|
103
|
--
|
--
|
--
|
--
|